Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference
Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, announced its CEO Iraj Ali will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on May 13, 2021, at 9:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, announced its CEO Iraj Ali will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on May 13, 2021, at 9:30 a.m. ET. This event highlights the company's work in developing precision T cell therapies targeting clonal neoantigens for treating solid tumors, with ongoing trials for non-small cell lung cancer and melanoma. A webcast of the presentation will be available on their website.
Details
News Market Reaction – ACHL
The recorded move for ACHL in the trading session of this news was +3.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021, at 9:30 a.m. ET / 2:30 p.m. BST.
A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website.
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Further information:
Lee M. Stern – VP, IR & External Communications
+1 (332) 373-2634
l.stern@achillestx.com
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
achillestx@consilium-comms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.